Merger method: Solux absorbs Aribio, and the surviving entity will be renamed to Aribio. Solux maintains its KOSDAQ listing status.
Merger ratio: 1 Solux common share for 2.0610695 Aribio common shares. Solux merger price: 10,136 KRW (par 500), Aribio merger price: 20,891 KRW (par 500).
New shares issued: 52,737,384 common shares to Aribio shareholders. This represents an approximately 107% increase over Solux's existing shares (49,337,244), causing significant dilution for existing shareholders.
Merger purpose: Create synergy by combining LED lighting and biotechnology (Alzheimer's treatment), improve management efficiency, and maximize corporate value.
Appraisal rights: Solux's estimated buyback price is 10,719 KRW. Dissenting shareholders can exercise rights from Aug 25 to Sep 14, 2026. If total buyback amount exceeds 1.5B KRW (Solux) or 3B KRW (Aribio), the merger may be terminated.
Financial status: Solux assets 511B KRW, liabilities 232.4B KRW (equity ratio ~54.5%). Aribio assets 147B KRW, liabilities 71.6B KRW, net loss of 24.6B KRW in 2023, indicating continued losses.
Schedule: Shareholders' meeting Aug 25, 2026; merger date Sep 29, 2026; new shares listing expected Oct 21, 2026.
[AI Comprehensive Analysis]The massive issuance of new shares (107% dilution) will significantly impair existing shareholders' equity value. With the current stock price (5,520 KRW) far below the merger price (10,136 KRW), short-term downward pressure exists. Although the entry into the biotech sector provides long-term growth potential, it is unlikely to offset the immediate dilution effect.
KOSDAQ Filing Information
Filing: [Correction of Description] Report On Major Matters (Decision On Company Merger)